

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
JK	7	PCT	WO 00/69810		NOVO NORDISK A/S & AGOURON PHARMACEUTICALS, INC.	11/23/2000
JK	8	PCT	WO 00/39088		NOVO NORDISK A/S & AGOURON PHARMACEUTICALS, INC.	07/06/2000
JK	9	PCT	WO 99/01423corrected version		NOVO NORDISK A/S & ALANEX CORPORATION	01/14/1999
JK	10	PCT	WO 99/01423		NOVO NORDISK A/S & ALANEX CORPORATION	01/14/1999
JK	11	PCT	WO 98/04528 A2		BAYER CORPORATION & BAYER AKTIENGESELLSCHAFT	02/05/1998
JK	12	PCT	WO 98/04528 A3		BAYER CORPORATION & BAYER AKTIENGESELLSCHAFT	02/05/1998
JK	13	PCT	WO 99/22108		MERCK & CO., INC.	05/28/1998
JK	14	PCT	WO 99/22109		MERCK & CO., INC.	05/28/1998
JK	15	PCT	WO 97/16442		MERCK & CO., INC.	05/09/1997
JK	16	PCT	WO 98/21957		MERCK & CO., INC.	05/28/1998

Examiner Signature	<i>Lam L. Stock</i>	Date Considered	2/17/05
--------------------	---------------------	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

## Sheet

2

9

5

**COMPLETE IF KNOWN**

**Application Number** 10/701,186

**Filing Date** November 4, 2003

**First Named Inventor**

Group Art Unit 1626

Examiner Name Stockton

Attorney Docket Number 21167

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
SS	17	PCT	WO 99/46267		NOVO NORDISK A/S	09/16/1999
SS	18	PCT	WO 99/32448		AMGEN, INC.	07/01/1999
SS	19	PCT	WO 99/32448 corrected version		AMGEN, INC.	07/01/1998
SS	20	PCT	WO 02/18335		YAMANOUCHI PHARMACEUTICAL CO., LTD.	03/07/2002
SS	21	PCT	WO 01/58890		ASTRAZENECA AB	08/16/2001
SS	22	PCT	WO 01/46165		NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	06/28/2001
SS	23	PCT	WO 01/44226		PROTHERICS MOLECULAR DESIGN LIMITED	06/21/2001
SS	24	PCT	WO 01/40223 A2		NOVARTIS AG	06/07/2001
SS	25	PCT	WO 01/40223 A3		NOVARTIS AG	06/07/2001
SS	26	PCT	WO 01/36415		NOVARTIS AG	05/25/2001

Examiner  
Signature

Sam F. Shultz

Date Considered

2/17/05

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Parents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449 APTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet

3

91

5

**COMPLETE IF KNOWN**

Application Number	10/701,186
Filing Date	November 4, 2003
First Named Inventor	Joseph L. Duffy, et al.
Group Art Unit	1624
Examiner Name	Stockton
Attorney Docket Number	21167

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
SS	27	PCT	WO 01/32632 A2		ELI LILLY AND COMPANY	05/10/2001
SS	28	PCT	WO 01/32632 A3		ELI LILLY AND COMPANY	05/10/2001
SS	29	EP	0 263 071 A1		CIBA-GEIGY AG	04/06/1988
SS	30	EP	0 263 071 B1		CIBA-GEIGY AG	04/06/1988
SS	31	EP	0 253 259 A2		BAYER AG	01/20/1988
SS	32	EP	0 253 259 A3		BAYER AG	01/20/1988
SS	33	EP	0 193 885 A1		BASF	09/10/1986
SS	34	EP	0 193 885 B1		BASF	09/10/1986
SS	35	EP	0 202 538 A1		BAYER AG	11/26/1986
SS	36	EP	0 202 538 B1		BAYER AG	11/26/1986

Examiner  
Signature

Lam L. Stock

**Date Considered**

2/17/05

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

<p>Substitute for Form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE</b></p> <p><b>STATEMENT BY APPLICANT</b></p> <p>FB 0 6 2004 (use as many sheets as necessary)</p>		<b>COMPLETE IF KNOWN</b>	
		Application Number	10/701,186
		Filing Date	November 4, 2003
		First Named Inventor	Joseph L. Duffy, et al.
		Group Art Unit	1626
		Examiner Name	Stockton
4	of	5	Attorney Docket Number
Sheet			21167


## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
SS	37	EP	0 217 748 A2		CIBA-GEIGY	04/08/1987
SS	38	EP	0 217 748 B1		CIBA-GEIGY	04/08/1987
SS	39	FR	2 565 981		ADIR	12/20/1985
SS	40	FR	2 564 467		ADIR	11/22/1985
SS	41	DE	35 29 247 A1	-	BAYER AG	11/20/1986
SS	42	DE	36 24 304 A1		BAYER AG	01/28/1986
SS	43	DE	41 19 767 A1		ARZNEIMITTELWERK DRESDEN GmbH	02/15/2002
SS	44	DE	35 07 421 A1		BASF AG	09/04/1986
SS	45	JP	2002-50169		FUJI PHOTO FILM CO., LTD.	02/15/2002

Examiner Signature Lam F. Shieh Date Considered 2/17/05

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

5

COMPLETE IF KNOWN	
Application Number	10/701,186
Filing Date	November 4, 2003
First Named Inventor	Joseph L. Duffy et al.
Group Art Unit	1626
Examiner Name	Stockton

Attorney Docket Number 21167

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
SS	46	Guillon, Jean, et al., "Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non-peptide glucagon receptor antagonist", <i>Eur. J. Med. Chem.</i> , 33, pp. 293-308 (1998)
SS	47	Petersen, K. F., et al., "Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans", <i>Diabetologia</i> , 44, pp. 2018-2024 (2001)
SS	48	Ladouceur, Gaetan, H., et al., "Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 12, pp. 461-464 (2002)
SS	49	Cascieri, Margaret, A., "Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor, <i>The Journal of Biological Chemistry</i> , Vol. 274, Issue of March 26, pp. 8694-8697 (1999)
SS	50	de Laszlo, Stephen, E., "Potent, Orally Absorbed Glucagon Receptor Antagonists", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 9, pp. 641-646 (1999)
SS	51	Madsen, Peter, et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human glucagon Receptor Antagonists", <i>J. Med Chem</i> , 41, pp. 5150-5157 (1998)
SS	52	Ling, Anthony, et al., "Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists", <i>J. Med. Chem</i> , 44, pp. 3141-3149 (2001)
SS	53	Ling, Anthony, et al., "Human Glucagon Receptor Antagonists Based on Alkylidene Hydrazides", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 12, pp. 663-666 (2002)
SS	54	Collins, Judith, L., "CP-99,711: A Non-Peptide Glucagon Receptor Antagonist", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 2, No. 9, pp. 915-918 (1992)
SS	55	Parker, Janice, C., "Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and human Hepatocytes", <i>Diabetes</i> , Vol. 49, pp. 2079-2086 (December 2000)
SS	56	Connell, Richard, D., "Glucagon antagonists for the treatment of Type 2 diabetes", <i>Expert Opinion on Therapeutic patents</i> , 9(6), pp. 701-709 (1999)
SS	57	Madsen, P., et al., "Advances in Non-Peptide Glucagon Receptor Antagonists", <i>Current Pharmaceutical Design</i> , 5, pp. 683-691 (1999)

Examiner Signature

Date Considered

2/17/05

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003